Alendronate for Osteonecrosis in Adults With Sickle Cell Disease

Part of paid clinical trials in Sacramento, California.

Sponsor
University of California, Davis
Study ID
NCT06016634
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Alendronate Sodium — DRUG
    Administer oral alendronate 70 mg once a week x 24 weeks to all study participants

Study Details

A prospective, single-arm, intervention study of oral alendronate in adults with sickle cell disease and osteonecrosis

Key Dates

Start date
Mar 9, 2026
Status verified
Apr 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2027

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Alendronate group
    Single-arm prospective cohort of 30 adult with SCD

Primary Outcome Measure

Recruitment and retention rates [ Time Frame: up to 28 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
UC Davis Comprehensive Cancer CenterSacramentoCalifornia95817
Leyla Y Teos, PhD
[email protected]
916-460-2749
Oyebimpe O Adesina, MD, MS
[email protected]
(916) 703-5166
Oyebimpe O Adesina, MD, MS (PRINCIPAL_INVESTIGATOR)

Find similar trials in Sacramento, CA

By condition
Sickle cell disease
By research site
UC Davis Comprehensive Cancer Center· Sacramento, CA

Related Studies